Dr. Cambou is President and CEO of a "diagnostic/biomarker" company he founded in October 2004. Prior to this move he was with Birchmere Ventures, a Pittsburgh-based venture capital firm, where he lead new life sciences efforts. At Birchmere Ventures he led their investments in Renal Solutions Inc., Eximias Pharmaceuticals and Metabolex Inc.

In 1999 Dr. Cambou co-founded Principia Pharmaceuticals, a spinout of Aventis Pharma. The company was acquired in 2000 by Human Genome Sciences in a $120 million stock transaction. Following this acquisition, Dr. Cambou joined Human Genome Sciences in the capacity of Vice President, Business Development.

Dr. Cambou is an engineer in Agronomy and a graduate in Molecular Biology from the Pasteur Institute. He obtained his Ph.D. from the University of Technology of Compiegne in Biochemistry and Enzymology and spent two years as a Post-Doctoral Fellow in Enzymology at Massachusetts Institute of Technology.

Dr. Cambou started his career with Roussel-Uclaf (now Aventis Pharma) as Senior Scientist in Biotechnology. He later joined Farmitalia Carlo Erba (now Pharmacia) and then Rhone-Poulenc Rorer/RPR (now Aventis Pharma) in various research and development capacities. While with Rhone-Poulenc Rorer, he spent two years in Japan as Chief Scientific Officer of the oncology joint venture RPR-Chugai Pharmaceuticals. This effort led to the approval of Granocyte (rG-CSF) in Europe and Japan as well as two monoclonal antibodies at various stages of clinical development in Japan. Dr. Cambou then moved into business development, relocating to the U.S. as Head of Biotechnology Evaluation for Centeon (now Aventis Behring), an RPR-Hoescht biopharmaceutical joint venture. At Centeon, He was responsible for early-stage in/out-licensing as well as M&A transactions in the biotechnology sector. In this capacity he was involved or led various acquisitions such as Immune Applied Sciences/US, Delta Biotechnology/UK, Genvec/Germany as well as new partnerships with Merck, Medarex, Inhale Corp., Kaketsuken/Japan and Bayer Biologics.

In 1999 Dr. Cambou co-founded Principia Pharmaceuticals, a spinout of Aventis Pharma. The company was acquired in 2000 by Human Genome Sciences in a $120 million stock transaction. Following this acquisition, Dr. Cambou joined Human Genome Sciences in the capacity of Vice President, Business Development. To date, the albumin fusion technology developed by Principia/HGS has already led to three product candidates in HGS' clinical pipeline.

In May 2002, Dr. Cambou joined Birchmere Ventures, a Pittsburgh-based venture capital firm to lead their new life sciences efforts. In March 2003, this endeavor has led to a partnership with Bay City Capital based in San Francisco, the 15th largest life sciences venture capital firm in the world. Together the Birchmare-Bay City Capital joint-venture is managing a new technology and life sciences fund/BVIII. BVIII is designed to capitalize on the under-served hubs on innovation in the mid-Atlantic region. During his tenure with Birchmere Ventures, Dr. Cambou led three investments (Renal Solutions Inc., Eximias Pharmaceuticals and Metabolex Inc.).

More recently, Dr. Cambou became the President and CEO of a "diagnostic/biomarker" company he founded in October 2004.

Dr. Cambou is an engineer in Agronomy and majored in Microbiology at the National Institute of Agronomy in France. He is a graduate in Molecular Biology from the Pasteur Institute. He obtained his Ph.D. from the University of Technology of Compiegne in Biochemistry and Enzymology and spent two years as a Post-Doctoral Fellow in Enzymology at Massachusetts Institute of Technology under the leadership of Professor Alexander Klibanov. Dr. Cambou also received an M.B.A. at Ecole Superieure des Sciences Economiques et Commerciales, in Paris.